Download - History of Validation
Biometrix Corporation (800)-890-8909
1
Validation History
(with some current issues)
Biometrix Corporation (800)-890-8909
2
History
Prior to 1978, drug product quality and sterility was based solely on finished product testing.
Sterile products – USP Sterility Testing
Biometrix Corporation (800)-890-8909
3
History
USP Sterility Test
Defect Rate Detection Probability
1% 18%
5% 64%
15% 95%
30% 99%
Batch Size 60,000 units
Biometrix Corporation (800)-890-8909
4
History
Serious Incidents
Thalidomide – 1962
Septicimia – 1970’s
Biometrix Corporation (800)-890-8909
5
History
Septicemia outbreaks greatest impact Sterility problems with large volume parenterals
(LVP) 54 deaths and 410 serious injuries FDA inspections, product recalls and plant closure
Biometrix Corporation (800)-890-8909
6
History
LVP and SVP facilities problems
Inadequate process specs, SOPs and test data No EM specs, SOPs, and test data
Biometrix Corporation (800)-890-8909
7
History
1976: FDA proposed changes to the GMP’s Focused on Sterilization Procedures, Steam and
Dry Heat Sterilization, ETO, Depyrogenation, SIP, and filtration.
Terms such as Validation, Protocol, and Qualification began to be used.
Biometrix Corporation (800)-890-8909
8
History
“Validation is a documented program which provides a high degree of assurance that a specific process will consistently and repeatedly produce a product meeting its predetermined specification and quality attributes.”
Biometrix Corporation (800)-890-8909
9
History
FDA expanded the need for validation Aseptic processing Filtration Environmental Controls Sanitation Water Systems Etc.
Biometrix Corporation (800)-890-8909
10
History
FDA stepped things up.
Companies started defensively. FDA’s strength moved things along.
Biometrix Corporation (800)-890-8909
11
History
FDA recognized potential improvements
In 1978, revised GMP’s introduced.
Biometrix Corporation (800)-890-8909
12
What Must Be Validated
The CGMPs (1978) state that any facilities or systems used in the manufacturing, processing, packing or holding of a drug or device shall conform with Current Good Manufacturing Practice Guidelines, to assure the product meets its predetermined quality characteristics.
Biometrix Corporation (800)-890-8909
13
What Must Be Validated
Processes: Sterilization Systems Aseptic Filling Operations Solution Preparation Systems WFI (Water For Injection) Systems Environmental Systems
Biometrix Corporation (800)-890-8909
14
What Must Be Validated
Processes (continued): Utilities Sanitation Processes Filtration Processes Labeling Systems Packaging Systems
Biometrix Corporation (800)-890-8909
15
History
Pharmaceutical manufacturers realize benefits.
Reduction of down time and defective product Improved Quality Reduced risk of Product recalls, Fatalities,
Lawsuits, etc.
Biometrix Corporation (800)-890-8909
16
Current Issues
For first 20 years of Validation, many problems “Over validation” More documents vs. scientific basis Validation for all processes was treated the same Rising cost Stifled Innovation
Biometrix Corporation (800)-890-8909
17
Current Issues
Improvements in the last 10 years
FDA improved training and consistency FDA incorporated Pre Approval Inspections FDA offered Parametric Release
Biometrix Corporation (800)-890-8909
18
Current Issues – Part 11
21 CFR part 11 Acceptance of the following in place of paper
records Electronic records Electronic signatures Handwritten signatures executed to electronic
records Effective on August 20, 1997
Biometrix Corporation (800)-890-8909
19
Current Issues – Part 11
1991: Industry met with FDA about paperless record systems
A proposed rule was issued in 1994 Final Rule 21 CFR part 11 became effective on
August 20, 1997 Compliance Policy Guide and several Guidance
Documents were issued in 1999-2002
Biometrix Corporation (800)-890-8909
20
Current Issues – Part 11
Objectives Behind FDA 21 CFR Part 11
Permit introduction of new technology Allow FDA to operate on same technological level as industry Preserve & protect electronic GxP records Prevent fraudulent changes to electronic records Protect product quality
Biometrix Corporation (800)-890-8909
21
Current Issues – Part 11
Interpretations Created Great Confusion
Scope unclear, broad interpretations Unnecessary controls and cost without adding to public safety Restricted use of technology and discourage innovation March, 2003: FDA will exercise “enforcement discretion” and
withdrew all guidance documents August, 2003: FDA issued the Scope and Application Guidance
Biometrix Corporation (800)-890-8909
22
Current Issues – Part 11
Part 11 Scope and Application Guidance Summary
FDA is re-examining part 11 FDA anticipates changes to part 11 Enforcement Discretion
Biometrix Corporation (800)-890-8909
23
Current Issues –CGMPs for the 21st Century Health and Human Services efforts to improve and streamline the
regulatory process
State-of-the-art pharmaceutical science to be used regulatory review and inspection
Encouraging the adoption of new technology Assessing the applicable CGMP requirements Use risk-based approach to strengthen public health protection Enhancing the consistency and coordination of FDA’s drug quality oversight
Biometrix Corporation (800)-890-8909
24
Current Issues –CGMPs for the 21st Century
Pharmaceutical CGMPs for the 21st Century
Science Based Risk Assessment Target Inspections on areas of greatest risk Uses FDA resources more effectively and
efficiently Will place more emphasis on sterile products